CD8A and neoplasm: In this study, we developed a peptide:HLA binding affinity assay (defined as the “blue peptide assay”) to assess a panel of peptide variants with a large spectrum of class I HLA binding capacities in two tumor antigen-specific CD8 T cell model systems relevant for cancer vaccination and adoptive cell transfer immunotherapy.